TradingKey

关于 Syndax Pharmaceuticals Inc 公司

Syndax Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发癌症疗法。其候选产品包括 revumenib 和 axatilimab。该公司正在开发 revumenib，这是一种强效、选择性、小分子抑制剂，可抑制 menin-MLL 结合相互作用，用于治疗 KMT2A 重排（也称为混合谱系白血病重排）、急性白血病（包括急性淋巴细胞白血病和急性髓细胞白血病 (AML)）和核磷蛋白 1（也称为 NPM1，突变体 A）。该公司还在探索使用 revumenib 治疗实体瘤，特别是其在转移性结直肠癌中的活性。该公司还在开发 axatilimab，这是一种单克隆抗体，可阻断慢性移植物抗宿主病 (cGVHD) 以及特发性肺纤维化中的集落刺激因子 1 受体 (CSF-1R)。 Entinostat 是一种口服小分子候选产品，对癌细胞和免疫调节细胞有直接作用。

公司简介

公司代码SNDX

公司名称Syndax Pharmaceuticals Inc

上市日期Mar 03, 2016

CEOMr. Michael A. Metzger

员工数量270

证券类型Ordinary Share

年结日Mar 03

公司地址730 Third Avenue

城市NEW YORK

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编10017

电话17814191400

网址https://syndax.com/

公司代码SNDX

上市日期Mar 03, 2016

CEOMr. Michael A. Metzger

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Michael A. Metzger

Chief Executive Officer, Director

298.66K

-2.46%

Mr. Dennis G. Podlesak

Independent Chairman of the Board

127.33K

-11.16%

Mr. Keith A. Katkin, CPA

Independent Director

75.00K

+15.38%

Mr. Steven (Steve) Closter

Chief Commercial Officer

70.90K

--

Mr. Pierre Legault, CPA

Independent Director

65.00K

-10.96%

Nicholas A.J. Botwood ,

Head - Research and Development, Chief Medical Officer

--

Ms. Jennifer A. Jarrett

Independent Director

--

Dr. Aleksandra Rizo, M.D., Ph.D.

Independent Director

--

Mr. Keith A. Goldan, CPA

Chief Financial Officer

--

Dr. Martin H. Huber, M.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Michael A. Metzger

Chief Executive Officer, Director

298.66K

-2.46%

Mr. Dennis G. Podlesak

Independent Chairman of the Board

127.33K

-11.16%

Mr. Keith A. Katkin, CPA

Independent Director

75.00K

+15.38%

Mr. Steven (Steve) Closter

Chief Commercial Officer

70.90K

--

Mr. Pierre Legault, CPA

Independent Director

65.00K

-10.96%

Nicholas A.J. Botwood ,

Head - Research and Development, Chief Medical Officer

--

收入明细

暂无数据

暂无数据

业务

地区

暂无数据

股东统计

更新时间: 5月17日周六

持股股东

股东类型

持股股东

占比

Kynam Capital Management LP

9.90%

BlackRock Institutional Trust Company, N.A.

7.92%

The Vanguard Group, Inc.

5.64%

Eversept Partners, LP

4.90%

Point72 Asset Management, L.P.

4.66%

Other

66.98%

持股股东

占比

Kynam Capital Management LP

9.90%

BlackRock Institutional Trust Company, N.A.

7.92%

The Vanguard Group, Inc.

5.64%

Eversept Partners, LP

4.90%

Point72 Asset Management, L.P.

4.66%

Other

66.98%

股东类型

持股股东

占比

Hedge Fund

54.88%

Investment Advisor

31.18%

Investment Advisor/Hedge Fund

18.83%

Research Firm

9.33%

Venture Capital

4.95%

Individual Investor

1.31%

Pension Fund

0.80%

Sovereign Wealth Fund

0.48%

Bank and Trust

0.32%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

452

105.51M

122.62%

-9.86M

2025Q1

465

105.51M

122.65%

-11.55M

2024Q4

466

101.18M

117.63%

-2.44M

2024Q3

454

91.99M

107.96%

-12.90M

2024Q2

424

90.42M

106.49%

-16.61M

2024Q1

417

93.25M

109.83%

-11.76M

2023Q4

407

91.08M

107.54%

+9.06M

2023Q3

394

77.71M

113.61%

-12.98M

2023Q2

385

77.69M

113.93%

-12.13M

2023Q1

384

79.89M

118.60%

-9.29M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Kynam Capital Management LP

8.52M

9.9%

--

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.81M

7.92%

-562.84K

-7.63%

Mar 31, 2025

The Vanguard Group, Inc.

4.86M

5.64%

-10.90K

-0.22%

Mar 31, 2025

Eversept Partners, LP

4.21M

4.9%

+3.87M

+1126.64%

Mar 31, 2025

Point72 Asset Management, L.P.

4.01M

4.66%

+2.09M

+109.25%

Mar 31, 2025

State Street Global Advisors (US)

3.97M

4.62%

+54.22K

+1.38%

Mar 31, 2025

Goldman Sachs & Company, Inc.

3.46M

4.02%

-2.08M

-37.54%

Mar 31, 2025

Citadel Advisors LLC

2.91M

3.39%

+1.83M

+167.47%

Mar 31, 2025

BofA Global Research (US)

2.87M

3.34%

+2.63M

+1069.41%

Mar 31, 2025

Sofinnova Investments, Inc

2.28M

2.64%

+1.62M

+245.45%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

Tema Oncology ETF

0.92%

Virtus LifeSci Biotech Clinical Trials ETF

0.79%

SPDR S&P Biotech ETF

0.3%

Simplify Health Care ETF

0.18%

Direxion Daily S&P Biotech Bull 3X Shares

0.17%

Inspire Small/Mid Cap ESG ETF

0.15%

ProShares Ultra Nasdaq Biotechnology

0.09%

Invesco Nasdaq Biotechnology ETF

0.09%

iShares Biotechnology ETF

0.08%

Nuveen ESG Small-Cap ETF

0.08%

Tema Oncology ETF

占比0.92%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.79%

SPDR S&P Biotech ETF

占比0.3%

Simplify Health Care ETF

占比0.18%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.17%

Inspire Small/Mid Cap ESG ETF

占比0.15%

ProShares Ultra Nasdaq Biotechnology

占比0.09%

Invesco Nasdaq Biotechnology ETF

占比0.09%

iShares Biotechnology ETF

占比0.08%

Nuveen ESG Small-Cap ETF

占比0.08%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Syndax Pharmaceuticals Inc

9.965USD

Syndax Pharmaceuticals Inc

9.965

概览

公司

财务